Plaque Psoriasis Skin Clearance | COSENTYX® (secukinumab)
Pediatric PsO Treatment Information | COSENTYX® (secukinumab) | HCP
A multicenter, randomized, open-label pilot trial assessing the efficacy and safety of etanercept 50 mg twice weekly followed by etanercept 25 mg twice weekly, the combination of etanercept 25 mg twice weekly
Pediatric Psoriasis Before & After Results | Taltz® (ixekizumab)
JCM | Free Full-Text | Use of Guselkumab for the Treatment of Moderate-to-Severe Plaque Psoriasis: A 1 Year Real-Life Study
Data from the Otezla ESTEEM Clinical Trial | Otezla® (apremilast) Healthcare Professional Site
Figure 2 | Exposure–Response Relationships for the Efficacy and Safety of Risankizumab in Japanese Subjects with Psoriasis | SpringerLink
STELARA® (ustekinumab) Efficacy Data: Moderate to Severe Plaque Psoriasis
A 50% reduction in the Psoriasis Area and Severity Index (PASI 50) is a clinically significant endpoint in the assessment of psoriasis - ScienceDirect
Novartis' Cosentyx™ two-year data shows sustained effect and favorable safety profile in psoriasis patients | Novartis
SKYRIZI® Efficacy In Moderate to Severe Plaque Psoriasis (Ps)
Figure 2 | Efficacy and Safety of Brodalumab in Patients with Moderate-to-Severe Plaque Psoriasis and Skin of Color: Results from the Pooled AMAGINE-2/-3 Randomized Trials | SpringerLink
Plaque Psoriasis Efficacy | Enbrel® (etanercept)
Major Secondary Endpoints: Moderate to Severe Plaque PsO | TREMFYA® (guselkumab) HCP
Plaque Psoriasis Efficacy | Enbrel® (etanercept)
Moderate to severe plaque psoriasis | CIMZIA® (certolizumab pegol)
a) PASI-75 response rate for the North American population through... | Download Scientific Diagram
Improvement in Psoriasis Symptoms and Physical Functioning with Secukinumab Compared with Placebo and Etanercept in Subjects with Moderate-to-Severe Plaque Psoriasis and Psoriatic Arthritis: Results of a Subanalysis from the Phase 3 Fixture
Proportions of patients who achieved (a) PASI-75 and (b) PASI-50 and... | Download Scientific Diagram
Time course of PASI 75, PASI 90, sPGA 0/1, and DLQI overall score of... | Download Scientific Diagram
Perspectives in Psoriasis: Assessing Treatment Efficacy—Which Measures, What Do They Tell Us? - ppt download
PASI-75 Response with Otezla in the Treatment of Moderate to Severe Plaque Psoriasis — Efficacy | Otezla® (apremilast) Healthcare Professional Site
Novartis' plaque psoriasis drug keeps skin clear 4 years post treatment
PASI-75 and PASI-90 responder rates at weeks 4, 12, 24, and 52.... | Download Scientific Diagram
PASI-75 Response with Otezla in the Treatment of Moderate to Severe Plaque Psoriasis — Efficacy | Otezla® (apremilast) Healthcare Professional Site
Exposure–Response Relationships for Efficacy and Safety of Risankizumab in Phase II and III Trials in Psoriasis Patients - Khatri - 2020 - Clinical Pharmacology & Therapeutics - Wiley Online Library
